Lung Cancer Research Review, Issue 77
In this issue:
Zenocutuzumab in NRG1 fusion-positive cancers
Primary tumour SBRT, mediastinal chemo-RT and adjuvant immunotherapy for locally advanced NSCLC
5-year survival in advanced NSCLC with PD-L1 ≥50% treated with first-line pembrolizumab
Bodyweight gain with alectinib for ALK+ NSCLC
Datopotamab deruxtecan vs. docetaxel for advanced/metastatic NSCLC
Pemetrexed and platinum ± pembrolizumab for EGFR-mutated, metastatic nonsquamous NSCLC
Osimertinib ± ramucirumab in EGFR-mutated metastatic NSCLC
Durvalumab ± tremelimumab + chemotherapy in first-line metastatic NSCLC
Nivolumab + ipilimumab-based treatment in metastatic NSCLC and tumour PD-L1 <1%: long-term survival
Sunvozertinib for EGFR-TKI-resistant NSCLC with EGFR mutations
Expert contributor
Dr Sagun Parakh
Dr Sagun Parakh is a Consultant Medical Oncologist at Austin Hospital, specialising in lung cancer and primary brain tumours. After obtaining his fellowship, he completed his PhD at Olivia Newton-John Cancer Research Institute (ONJCRI) focusing on the development of a novel first-in-class anti-ErbB2 antibody. He is the head of the Lung Oncology Clinic at the […]
Latest Publications and Videos
Stay up to date with our latest clinical information.
Explore Research Review Publications and Videos
Dive into our publications and videos content from over 50 areas of medicine including Cardiology, Diabetes, Oncology, Haematology and Psychiatry.
Terms and Conditions
Website terms of use
By using our website, you agree to follow these terms and conditions.
Privacy policy
We take your privacy seriously. To understand how we collect, use, and protect your information, please read our Privacy Policy, which is part of these terms.
Copyright and use of website content
The content of our website is protected by copyright, trademarks, and other legal rights. You can: view, download, or print a single copy of content for your personal or professional use.
You cannot: copy, modify, or distribute website content, or use our website content for commercial purposes or in other works without permission.
Links to third-party websites
The Research Review website may link to third-party websites for your convenience. However:
We do not endorse or approve their products, services, or actions.
We are not responsible for their content or how they operate.
There is no formal partnership between us and third parties unless we clearly state otherwise.
Disclaimer and limitation of liability
We do our best to keep the information on our website accurate, but we do not guarantee that it is always correct or up to date.
To the fullest extent allowed by law, we are not responsible for:
Any loss, damage, or costs you may suffer from using (or being unable to use) our website.
Any decisions you make based on the information provided.
Any business losses, such as lost profits, lost data, or business interruptions.
Governing law
These terms are governed by New Zealand law. If there is a dispute, it must be resolved in a New Zealand court.